

# Real-World Head-to-Head Analysis of Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide versus Enzalutamide in the United States


Neal Shore, Benjamin Lowentritt, Ibrahim Khilfeh, Carmine Rossi, Shawn Du, Frederic Kinkead, Lilian Diaz, Dominic Pilon, Lorie Ellis, Mehmet A. Bilen

Atlantic Urology Clinics, Myrtle Beach, South Carolina, USA; Chesapeake Urology, Towson, Maryland, USA; Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, Pennsylvania, USA; Analysis Group, Inc., Montréal, Québec, Canada; Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

## What was the purpose of this study?

The study compared overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) who received treatment with apalutamide or enzalutamide

## Who was in the study and how was it carried out?



### Patient information came from medical and insurance databases

Information collected included medical background, prescriptions, deaths, and some other clinical information

## What were the results?

By 24 months, patients who started treatment with apalutamide were more likely to survive than those who started enzalutamide

24 months

87.6%  
Apalutamide

↑ 23% higher chance of survival with apalutamide at 24 months

84.6%  
Enzalutamide

## What do these results mean for individuals with mCSPC?

Individuals with mCSPC who started treatment with apalutamide were more likely to be alive at 24 months compared to those who started treatment with enzalutamide

## What were the limitations?

- As the study used clinical records, some information may be missing or incorrect, and not all deaths may have been recorded in the databases
- The patients included may not represent all people with mCSPC in the US, as the study data came from community urology practices only
- Longer follow-up may be needed to fully understand differences in survival

### Glossary of Terms

**Androgen Receptor Pathway Inhibitors (ARPIs):** These are drugs that block the action of androgens (male hormones) by binding to androgen receptors. Apalutamide and enzalutamide are examples of ARPIs used in the treatment of metastatic castration-sensitive prostate cancer (mCSPC).

**Metastatic Castration-Sensitive Prostate Cancer (mCSPC):** A type of prostate cancer that has spread to other parts of the body and still responds to treatments that lower testosterone levels.

**Overall Survival (OS):** The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.

**Real-World Evidence (RWE):** Clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data.



Scan the QR code for the full poster